Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | PLA2G2A | P14555 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17832775 | 0.89 | MAPT (0.45) | MAPTKDM4ELMNAALDH1A1 | |
| SCHEMBL17824527 | 0.87 | DYRK1A (0.43) | MAPTKDM4ELMNAALDH1A1PDE3B | |
| SCHEMBL17824436 | 0.78 | KDM4E (0.48) | MAPTKDM4ETP53ALDH1A1PDE3B | |
| SCHEMBL17824410 | 0.75 | ALDH1A1 (0.41) | MAPTKDM4ELMNATP53ALDH1A1 | |
| SCHEMBL31345618 | 0.74 | KDM4E (0.56) | MAPTKDM4ETDP1LMNATP53 | |
| SCHEMBL26617970 | 0.74 | KDM4E (0.56) | MAPTKDM4ETDP1LMNATP53 | |
| SCHEMBL17802324 | 0.73 | NPSR1 (0.40) | MAPTKDM4ELMNAALDH1A1TSHR | |
| SCHEMBL17832802 | 0.72 | L3MBTL1 (0.42) | MAPTKDM4ETDP1LMNAALDH1A1 | |
| SCHEMBL26617774 | 0.72 | KDM4E (0.57) | MAPTKDM4ETDP1LMNATP53 | |
| SCHEMBL6824431 | 0.72 | KDM4E (0.52) | MAPTKDM4ELMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107001364-B | Pesticidally active tetracyclic derivatives with sulfur-containing substituents | 先正达参股股份有限公司 | 2020-06-16 | — | — | CN | disclosed |
| EP-3230284-B1 | PESTICIDALLY ACTIVE TETRACYCLIC DERIVATIVES WITH SULFUR CONTAINING SUBSTITUENTS | SYNGENTA PARTICIPATIONS AG (CH) | 2020-04-15 | — | — | EP | disclosed |
| US-10308650-B2 | Pesticidally active tetracyclic derivatives with sulfur containing substituents | SYNGENTA PARTICIPATIONS AG (CH) | 2019-06-04 | — | — | US | disclosed |
| US-20170349581-A1 | PESTICIDALLY ACTIVE TETRACYCLIC DERIVATIVES WITH SULFUR CONTAINING SUBSTITUENTS | SYNGENTA PARTICIPATION AG (CH) | 2017-12-07 | — | — | US | disclosed |
| EP-3230284-A1 | PESTICIDALLY ACTIVE TETRACYCLIC DERIVATIVES WITH SULFUR CONTAINING SUBSTITUENTS | Syngenta Participations AG (CH) | 2017-10-18 | — | — | EP | disclosed |
| WO-2016091731-A1 | PESTICIDALLY ACTIVE TETRACYCLIC DERIVATIVES WITH SULFUR CONTAINING SUBSTITUENTS | SYNGENTA PARTICIPATIONS AG (CH) | 2016-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10308650-B2 | Pesticidally active tetracyclic derivatives with sulfur containing substituents | DDT, TST, ACHE | MAPT 407/4885KDM4E 3650/4885TDP1 2163/4885 |
| US-20170349581-A1 | PESTICIDALLY ACTIVE TETRACYCLIC DERIVATIVES WITH SULFUR CONTAINING SUBSTITUENTS | DDT, TST, ACHE | MAPT 407/4885KDM4E 3650/4885TDP1 2163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.